Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Unknown 3Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 13Head & Neck 7Tumor-Agnostic 4Dermatologic 3Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Neoplasms 4Neoplasm Metastasis 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Immune Checkpoint Inhibitors × Tumor-Agnostic × Clear all
NCT07593053 2026-05-22

PIPO

Vall d'Hebron Institute of Oncology

Completed
586 enrolled
Tumor-Agnostic

Neoplasms

NCT03868046 2025-04-01

AUTENTIC

Hospital Universitario Araba

Completed
242 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05934214 2024-03-05

EXIT

Groupe Hospitalier Pitie-Salpetriere

Completed
141,630 enrolled
Tumor-Agnostic

Neoplasms

NCT03790488 2023-07-03

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Jounce Therapeutics, Inc.

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡